Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value—A Multicenter Study From South India

Shashidhar V. Karpurmath; Arun Seshachalam; Kalaiselvi Selvaraj; Priyadarshini Rajamani; Satish kumar; Neelesh Reddy; Baswant Malipatil; Roopa Sirigeri; Krishna Prasad; Krishna Reddy; Madhav Danthala; Karthik S. Udupa; Manjunath Nandennavar; Janarthinakani Murugesan; C. N. Patil; Parameswaran Anoop; Roshan Koshy Jacob; Mallikarjun Kalashetty; Krishnakumar Rathnam; Ramanan Ganapathy

doi:10.1016/j.clml.2019.09.606

Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value—A Multicenter Study From South India

Shashidhar V. Karpurmath^*, Arun Seshachalam, Kalaiselvi Selvaraj, Priyadarshini Rajamani, Satish kumar, Neelesh Reddy, Baswant Malipatil, Roopa Sirigeri, Krishna Prasad, Krishna Reddy, Madhav Danthala, Karthik S. Udupa, Manjunath Nandennavar, Janarthinakani Murugesan, C. N. Patil, Parameswaran Anoop, Roshan Koshy Jacob, Mallikarjun Kalashetty, Krishnakumar Rathnam, Ramanan Ganapathy

^*Corresponding author for this work

Department of Medical Oncology, Kasturba Medical College, Manipal

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

We found that the rate of decline of BCR-ABL1 (breakpoint cluster region-Abelson 1) is a better predictor of the molecular response in patients with chronic myeloid leukemia than the single 90-day value. The present retrospective cohort study of 90 patients is the first study in the Indian context comparing the rate of decline of BCR-ABLl against the single 90-day value.

Original language	English
Pages (from-to)	e205-e211
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
Issue number	5
DOIs	https://doi.org/10.1016/j.clml.2019.09.606
Publication status	Published - 01-05-2020

All Science Journal Classification (ASJC) codes

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2019.09.606

Cite this

Karpurmath, S. V., Seshachalam, A., Selvaraj, K., Rajamani, P., kumar, S., Reddy, N., Malipatil, B., Sirigeri, R., Prasad, K., Reddy, K., Danthala, M., Udupa, K. S., Nandennavar, M., Murugesan, J., Patil, C. N., Anoop, P., Jacob, R. K., Kalashetty, M., Rathnam, K., & Ganapathy, R. (2020). Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value—A Multicenter Study From South India. Clinical Lymphoma, Myeloma and Leukemia, 20(5), e205-e211. https://doi.org/10.1016/j.clml.2019.09.606

@article{d42ff315d4994641bf77f3ffde407ba3,

title = "Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value—A Multicenter Study From South India",

abstract = "We found that the rate of decline of BCR-ABL1 (breakpoint cluster region-Abelson 1) is a better predictor of the molecular response in patients with chronic myeloid leukemia than the single 90-day value. The present retrospective cohort study of 90 patients is the first study in the Indian context comparing the rate of decline of BCR-ABLl against the single 90-day value.",

author = "Karpurmath, {Shashidhar V.} and Arun Seshachalam and Kalaiselvi Selvaraj and Priyadarshini Rajamani and Satish kumar and Neelesh Reddy and Baswant Malipatil and Roopa Sirigeri and Krishna Prasad and Krishna Reddy and Madhav Danthala and Udupa, {Karthik S.} and Manjunath Nandennavar and Janarthinakani Murugesan and Patil, {C. N.} and Parameswaran Anoop and Jacob, {Roshan Koshy} and Mallikarjun Kalashetty and Krishnakumar Rathnam and Ramanan Ganapathy",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = may,

day = "1",

doi = "10.1016/j.clml.2019.09.606",

language = "English",

volume = "20",

pages = "e205--e211",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "5",

}

Karpurmath, SV, Seshachalam, A, Selvaraj, K, Rajamani, P, kumar, S, Reddy, N, Malipatil, B, Sirigeri, R, Prasad, K, Reddy, K, Danthala, M, Udupa, KS, Nandennavar, M, Murugesan, J, Patil, CN, Anoop, P, Jacob, RK, Kalashetty, M, Rathnam, K & Ganapathy, R 2020, 'Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value—A Multicenter Study From South India', Clinical Lymphoma, Myeloma and Leukemia, vol. 20, no. 5, pp. e205-e211. https://doi.org/10.1016/j.clml.2019.09.606

TY - JOUR

T1 - Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia

T2 - Is It Better Than Day-90 Value—A Multicenter Study From South India

AU - Karpurmath, Shashidhar V.

AU - Seshachalam, Arun

AU - Selvaraj, Kalaiselvi

AU - Rajamani, Priyadarshini

AU - kumar, Satish

AU - Reddy, Neelesh

AU - Malipatil, Baswant

AU - Sirigeri, Roopa

AU - Prasad, Krishna

AU - Reddy, Krishna

AU - Danthala, Madhav

AU - Udupa, Karthik S.

AU - Nandennavar, Manjunath

AU - Murugesan, Janarthinakani

AU - Patil, C. N.

AU - Anoop, Parameswaran

AU - Jacob, Roshan Koshy

AU - Kalashetty, Mallikarjun

AU - Rathnam, Krishnakumar

AU - Ganapathy, Ramanan

PY - 2020/5/1

Y1 - 2020/5/1

N2 - We found that the rate of decline of BCR-ABL1 (breakpoint cluster region-Abelson 1) is a better predictor of the molecular response in patients with chronic myeloid leukemia than the single 90-day value. The present retrospective cohort study of 90 patients is the first study in the Indian context comparing the rate of decline of BCR-ABLl against the single 90-day value.

AB - We found that the rate of decline of BCR-ABL1 (breakpoint cluster region-Abelson 1) is a better predictor of the molecular response in patients with chronic myeloid leukemia than the single 90-day value. The present retrospective cohort study of 90 patients is the first study in the Indian context comparing the rate of decline of BCR-ABLl against the single 90-day value.

UR - http://www.scopus.com/inward/record.url?scp=85081005216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081005216&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.09.606

DO - 10.1016/j.clml.2019.09.606

M3 - Article

AN - SCOPUS:85081005216

SN - 2152-2650

VL - 20

SP - e205-e211

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 5

ER -

Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value—A Multicenter Study From South India

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this